News
Zepbound beats Wegovy for weight loss
Digest more
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...
This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).
Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback